| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
tribbles pseudokinase 1 | 0.617 | 0.577 | 0.83 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | ||||||||
|
cyclin dependent kinase 9 | 0.498 | 0.769 | 8.9E-05 |
|
group | 0.010 | None | < 0.001 | 1 | 0 | 2018 | 2018 | ||||||||
|
iroquois homeobox 5 | 0.623 | 0.846 | 0.97 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2008 | 2008 | ||||||||
|
macrophage stimulating 1 pseudogene | 1.000 | 0.077 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2014 | 2014 | |||||||||
|
tubulin beta 3 class III | 0.486 | 0.808 | 2.6E-10 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2010 | 2010 | ||||||||
|
WAP four-disulfide core domain 2 | 0.729 | 0.308 | 0.79 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2008 | 2008 | ||||||||
|
prostate cancer associated transcript 29 | 0.861 | 0.154 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2014 | 2014 | |||||||||
|
follistatin | 0.513 | 0.731 | 0.98 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 1999 | 1999 | ||||||||
|
nuclear RNA export factor 1 | 0.531 | 0.885 | 0.98 |
|
group | 0.010 | None | < 0.001 | 1 | 0 | 2018 | 2018 | ||||||||
|
cyclase associated actin cytoskeleton regulatory protein 1 | 0.529 | 0.808 | 2.0E-02 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | ||||||||
|
cAMP responsive element binding protein 3 | 0.663 | 0.654 | 1.8E-05 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2015 | 2015 | ||||||||
|
coactivator associated arginine methyltransferase 1 | 0.601 | 0.692 | 1.00 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2006 | 2006 | ||||||||
|
CCAAT enhancer binding protein beta | 0.508 | 0.731 | 0.36 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2008 | 2008 | ||||||||
|
amyloid beta precursor protein binding protein 2 | 0.722 | 0.385 | 1.00 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2007 | 2007 | ||||||||
|
CCAAT enhancer binding protein delta | 0.570 | 0.769 | 0.61 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2005 | 2005 | ||||||||
|
lysine acetyltransferase 5 | 0.534 | 0.769 | 8.8E-02 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2018 | 2018 | ||||||||
|
prostate cancer expressed EZH2 associated transcript | 0.890 | 0.077 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2018 | 2018 | |||||||||
|
HIV-1 Tat interactive protein 2 | 0.608 | 0.577 | 5.4E-13 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2008 | 2008 | ||||||||
|
C-X-C motif chemokine ligand 13 | 0.472 | 0.731 | 0.83 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | ||||||||
|
sorbin and SH3 domain containing 1 | 0.554 | 0.769 | 1.5E-12 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | ||||||||
|
pre-mRNA processing factor 8 | 0.631 | 0.615 | 1.00 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2005 | 2005 | ||||||||
|
phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase | 0.711 | 0.346 | 2.8E-05 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 1998 | 1998 | ||||||||
|
prostate enriched lncRNA | 0.931 | 0.077 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2014 | 2014 | |||||||||
|
tripartite motif containing 16 | 0.670 | 0.462 | 3.2E-09 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2016 | 2016 | ||||||||
|
thioredoxin interacting protein | 0.490 | 0.731 | 0.16 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2002 | 2002 |